NCT06772610View on ClinicalTrials.gov

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2032

Conditions
NSCLCALKStage IAdjuvant Treatment
Interventions
DRUG

Ensartinib group

Ensartinib 200 mg, once daily, orally, for a continuous period of 2 years.

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER